Revolution Medicines

increase
Biotech

Royalty signs off $2B to bankroll Revolution's RAS cancer drug

Revolution secured the funding infusion from Royalty in return for a slice of the profits if Revolution's lead cancer drug makes it to market.
James Waldron Jun 24, 2025 9:00am
An artists illustration of a KRAS G12C mutation in non-small cell lung cancer

AACR: KRAS inhibitors pop in preclinical data debuts

Apr 11, 2024 4:30am
unravel break rope tie fray fall apart thread string

The unraveling of EQRx's low-cost drug dream

Oct 5, 2023 10:47am
merge MA railway train tracks path together

EQRx's low cost drug dream ends in Revolution

Aug 1, 2023 8:49am
ship sail explore sea discovery adventure

Sanofi sets Revolution back, sending lead asset to the docks

Dec 8, 2022 7:14am
picture of a paraglider

Agios replaces CEO after recent FDA nod—Chutes & Ladders

Jul 15, 2022 9:30am